mHSPC: Applying Data Toward Treatment Decision-Making

Evan Y. Yu, MD, discusses how community oncologists can critically weigh the evidence from studies on androgen deprivation therapy plus androgen receptor pathway inhibitors regimens by considering factors such as efficacy, safety, patient comorbidities, and treatment preferences, and how the collective trial results guide individualized treatment decision-making to optimize outcomes for patients with metastatic hormone-sensitive prostate cancer.

EP: 1.Introduction & Case 1 Presentation: mHSPC

EP: 2.Newly diagnosed Diagnosed mHSPC: Goals of Therapy

EP: 3.Newly Diagnosed mHSPC: First-Line Treatment Options

EP: 4.Newly Diagnosed mHSPC: Androgen Receptor Pathway Inhibitor Selection

EP: 5.Case 1 Presentation (cont): mHSPC

EP: 6.Phase 3 ARANOTE Study of ADT + Darolutamide

EP: 7.Phase 3 ARANOTE Study of ADT + Darolutamide: Safety

Now Viewing

EP: 8.mHSPC: Applying Data Toward Treatment Decision-Making

Video content above is prompted by the following:

What guidance can you offer community oncologists when critically weighing the evidence from these studies? Collectively, how are you applying the trial results toward treatment decision-making?

Recent Videos